newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology reports first quarter 2023 financial results and recent business highlights

Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR